» Articles » PMID: 21244578

Clinical Utility of Highly Sensitive Lens Culinaris Agglutinin-reactive Alpha-fetoprotein in Hepatocellular Carcinoma Patients with Alpha-fetoprotein <20 Ng/mL

Overview
Journal Cancer Sci
Specialty Oncology
Date 2011 Jan 20
PMID 21244578
Citations 57
Authors
Affiliations
Soon will be listed here.
Abstract

The Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein (AFP-L3) has been used as a diagnostic and prognostic marker of hepatocellular carcinoma (HCC). The analytical sensitivity of a conventional method for AFP-L3% is not sufficient in patients with a low AFP level. This study was performed to determine the clinical utility of a newly developed highly sensitive AFP-L3% (hs-AFP-L3%) assay in patients with an AFP level <20 ng/mL. In the cohort study, serum samples obtained from 270 patients with newly diagnosed HCC before treatment and 396 patients with chronic liver disease at Ogaki Municipal Hospital, in both of which the AFP level was <20 ng/mL, were measured for conventional AFP-L3% (c-AFP-L3%), hs-AFP-L3% and des-gamma-carboxy prothrombin (DCP). Diagnostic sensitivity and specificity of hs-AFP-L3% at a cut-off level of 5% were 41.5% and 85.1%, respectively, significantly increasing the sensitivity from 7.0% for c-AFP-L3%. Multivariate analysis identified hs-AFP-L3% as an independent factor associated with reduced long-term survival. The survival rate of patients with high hs-AFP-L3% (≥ 5%) before treatment was significantly poorer than that of patients with low hs-AFP-L3% (<5%) (P < 0.001). In patients with AFP <20 ng/mL, measurements of AFP-L3% by the highly sensitive method before treatment were more useful for diagnosis and prognosis of HCC than by the conventional method.

Citing Articles

Cell Cycle-Related LncRNA-Based Prognostic Model for Hepatocellular Carcinoma: Integrating Immune Microenvironment and Treatment Response.

Chen L, Wu G, Wu T, Shang H, Wang W, Fisher D Curr Med Sci. 2024; 44(6):1217-1231.

PMID: 39681799 DOI: 10.1007/s11596-024-2924-9.


Diagnostic performance of AI-based models versus physicians among patients with hepatocellular carcinoma: a systematic review and meta-analysis.

Al-Obeidat F, Hafez W, Gador M, Ahmed N, Abdeljawad M, Yadav A Front Artif Intell. 2024; 7:1398205.

PMID: 39224209 PMC: 11368160. DOI: 10.3389/frai.2024.1398205.


Redefining HCC Surveillance in India: A Call for Innovative and Inclusive Strategies.

Yelsangikar A, Patil P J Clin Exp Hepatol. 2024; 14(6):101474.

PMID: 39108278 PMC: 11298640. DOI: 10.1016/j.jceh.2024.101474.


Diagnostic and prognostic performances of GALAD score in staging and 1-year mortality of hepatocellular carcinoma: A prospective study.

Jitpraphawan O, Ruamtawee W, Treewatchareekorn M, Sethasine S World J Gastroenterol. 2024; 30(17):2343-2353.

PMID: 38813057 PMC: 11130574. DOI: 10.3748/wjg.v30.i17.2343.


Longitudinal surveillance of three biomarkers to predict recurrence of hepatocellular carcinoma after radical resection.

Tong J, Lu C, Lu C, Zheng S, Mao S Eur J Gastroenterol Hepatol. 2023; 35(10):1178-1185.

PMID: 37577836 PMC: 10756703. DOI: 10.1097/MEG.0000000000002610.